Want to see SE:PILA full AI Analyst Report?
PILA PHARMA AB (PILA) AI Stock Analysis
Top Page
PILA PHARMA AB
(Nasdaq OMX AB:PILA)
The score is primarily held down by weak financial performance—shrinking TTM revenue, large ongoing losses, and persistent negative free cash flow indicating continued reliance on external funding. Technical indicators are neutral to mildly supportive (positive MACD and price above longer-term averages), but they are not strong enough to offset the fundamental cash-burn profile. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 71.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 80.89K
- Price to Earnings (P/E)
- -3.8
- Beta (1Y)
- 0.16
- Revenue Growth
- -71.19%
- EPS Growth
- -23.18%
- Country
- Sweden
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PILA PHARMA AB Business Overview & Revenue Model
Company Description
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating...
How the Company Makes Money
As a clinical-stage pharmaceutical company, PILA PHARMA AB’s ability to generate recurring commercial revenue depends on successful drug development and subsequent commercialization or partnering. Specific, company-reported details on current revenue...
PILA PHARMA AB Financial Statement Overview
Summary
Financials reflect a pre-commercial, loss-making profile: TTM revenue fell sharply (-60.7%) from a low base, profitability is deeply negative (TTM net loss -16.8M) with negative margins, and cash flow shows persistent burn (TTM operating/free cash flow about -20.8M). The main offset is a low-leverage balance sheet with zero debt in recent periods, but recurring losses imply ongoing funding needs and dilution risk.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.74K | 1.13M | 775.00K | 1.46M | 1.88M | 719.23K |
| Gross Profit | -5.95M | -6.82M | -8.12M | 1.46M | 1.88M | 680.94K |
| EBITDA | -6.71M | -15.92M | -10.11M | -8.81M | -26.76M | -17.16M |
| Net Income | -16.77M | -16.86M | -11.24M | -9.93M | -26.78M | -17.21M |
Balance Sheet | ||||||
| Total Assets | 16.86M | 16.22M | 6.22M | 8.46M | 10.89M | 31.81M |
| Cash, Cash Equivalents and Short-Term Investments | 3.26M | 15.90M | 4.89M | 5.95M | 7.24M | 28.21M |
| Total Debt | 0 | 0 | 0 | 773.08K | 0 | 0 |
| Total Liabilities | 748.00K | 1.43M | 963.00K | 1.79M | 1.36M | 1.51M |
| Stockholders Equity | 16.11M | 14.78M | 5.26M | 6.66M | 9.53M | 30.30M |
Cash Flow | ||||||
| Free Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Operating Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 22.97M | 20.19M | 6.76M | 3.56M | -11.88M | 35.67M |
PILA PHARMA AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Neutral. The current price of 1.56 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.71, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PILA.
PILA PHARMA AB Peers Comparison
Overall Rating
- SE:PILA45Neutral
SE:MODTX41Neutral
SE:ONCOZ40Underperform
SE:ACE39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:PILA | 45Neutral | SEK 71.26M | -3.84 | -108.78% | ― | -71.19% | -23.18% |
| SE:MODTX | 41Neutral | SEK 31.19M | -1.02 | -177.45% | ― | ― | 0.22% |
| SE:ONCOZ | 40Underperform | SEK 85.84M | -1.62 | -2775.09% | ― | 115.26% | -230.43% |
| SE:ACE | 39Underperform | SEK 77.45M | -1.20 | -62.21% | ― | ― | 58.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:PILA | PILA PHARMA AB | 1.56 | -0.65 | -29.41% | |
| SE:ONCOZ | OncoZenge AB | 3.11 | -1.14 | -26.75% | |
| SE:ACE | Ascelia Pharma AB | 0.58 | -2.63 | -81.93% | |
| SE:MODTX | Modus Therapeutics Holding AB | 0.18 | -0.22 | -54.68% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026